Mustang Bio Inc MBIO

$0.36 -0.01 (-2.68%)

Valuation

Market cap
2,804,000
Revenue TTM
$0
Net income TTM
$-1,920,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
10,800
Avg volume
29,942
Day's range
$0.36 – $0.38
Shares out
7,577,000
Stochastic %K
0%
Beta
2.09
Analysts
Strong Buy
Price target
$8.00

Price

Company profile

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination M...

Show more

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children's hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
781 652 4500
Website
https://www.mustangbio.com
Address
95 Sawyer Road, Suite 110, Waltham, United States

Latest news

Stocktwits

dln101 Oct 20, 2:00 PM
$MBIO looks like next $PRSO at these levels 🤔💪
0 replies
FinSUN Oct 16, 10:01 PM
$MBIO what's the point of keeping it alive? oh yeah, a reverse split and a monstre new ATM fueled by false promises ?
0 replies
Radcon2017 Oct 16, 12:15 PM
$FBIO Ckecking in and I must say “What an awful mess of a share price here as it keeps trending lower”…Looking at how management has dealt with companies like MBIO whose price fades into oblivion…Just looking at these share price histories of $FBIO and $MBIO I have no desire to invest in FBIO, it has even caused me to pause my bullishness in $DERM. I actually held this stock in past years and made some money as I bought and sold it, but over-the last year plus, no interest whatsoever as the share price reflects a downtrend in value…It is not that I have stopped believing in the potential future value of DERM, FBIO, MBIO, etc., but the current market price trend of the common shares reflects another reality altogether…Believe it or not still hold a tiny position in MBIO that I acquired earlier this year…Wonder if we will ever get an update???
1 replies
SMM82 Oct 15, 8:12 PM
$MBIO Looks like they got the 180-day extension to regain compliance. Either reverse split or delisting in the next 6-months seems like the only options. Maybe Big Brother (FBIO) steps in to buy back its subsidiary assets, but that seems criminal given how the company was run into the ground and who sits on the Boards…
0 replies
stockplayer123 Oct 15, 8:10 PM
$MBIO granted a 180 day extension
0 replies
stockplayer123 Oct 14, 3:54 PM
$MBIO they have cash for a year per their latest 10Q. Why would they not get a 180 day extension? It appears they are SE compliant as well.
0 replies
Zellchair Oct 14, 12:37 PM
$FBIO $FBIOP $MBIO In a broad pipeline, there will always be more misses than hits, even though assets are typically acquired based on human data/results (i.e., not preclinical acquisitions). That is something one has to accept. What is harder to accept is how Fortress has treated—or rather, failed to act regarding several subsidiaries. Mustang is the latest example. This is a clear warning sign.
2 replies
SMM82 Oct 14, 12:27 PM
$MBIO via Fidelity...
0 replies